Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]

The purpose of this study is to assess the psychometric properties of a recently developed congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument.

Study Overview

• Status: Completed
• Conditions: Congenital Thrombotic Thrombocytopenic Purpura
• Intervention / Treatment: Other: No intervention

• Study Type: Observational
• Enrollment (Actual): 41

Contacts and Locations

Study Locations

• United Kingdom
  • Cambridge, United Kingdom, CB2 0QQ
    • Cambridge university hospital
  • London, United Kingdom, WC1E 6HX
    • University College London Hospital
• United States
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • AutoCruitment
  • Texas
    • Houston, Texas, United States, 77030
      • Houston Methodist Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Participants will be identified for inclusion by the Investigator (physician) and, if interested to participate, they will be asked to provide informed consent (and assent for adolescents 12 to 17 years). The legally authorized representative (LAR) of participating cTTP adolescents (ages 12 to 17 years) will provide informed consent on the adolescent's behalf. A qualified vendor will also be used to identify potentially eligible participants through various networks.

Description

Inclusion criteria:

1. The participant is an adolescent aged 12 to 17 years or an adult aged ≥18 years;
2. The participant has been diagnosed with congenital thrombotic thrombocytopenic purpura (cTTP) and is currently receiving prophylactic or on-demand treatment with fresh frozen plasma (FFP), or solvent detergent (S/D) plasma, or Von Willebrand Factor/Factor VIII (VWF/FVIII) concentrates;
3. In the instance that the participant is identified and recruited remotely (Direct-to-Patient (DtP) recruitment), access to the internet and possession of an internet-connecting device is required;
4. The participant has provided informed consent, and in the instance that the participant is an adolescent, a legal guardian has provided informed consent and the adolescent has provided assent.

Exclusion criteria:

1. The participant cannot read nor write;
2. The participant is non-English speaking;
3. The participant is currently participating in a clinical trial.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Participants with cTTP - adolescents; Adolescents aged 12 to 17 years	Other: No intervention; This is a non-interventional study.
Participants with cTTP - adults; Adults aged ≥18 years	Other: No intervention; This is a non-interventional study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline of Quality of life (QoL) outcomes: cTTP-specific PRO instrument	The congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument consists of 26 questions designed to assess the patient's experience of fatigue, joint, muscle, abdominal and chest pain in the previous 24 hours, neurologic manifestations, bruising, feelings of depression and mood alterations, and activity limitation in the past 7 days, and patient's attitudes, experienced side effects, work/school absences and travel impact associated with treatment received for TTP during the previous 2 weeks.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: PROMIS®-29	The Patient-Reported Outcomes Measurement Information System (PROMIS®)-29 Profile is a collection of 4-item short forms assessing anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and the ability to participate in social roles and activities, as well as a single pain intensity item. The individual scales for fatigue, pain interference, anxiety and depression, each being 5-point Likert scales, and the single pain intensity item, a 0 to 10 Numerical Rating Scale, will be used in this study. A higher score for all these scales indicate poorer HRQL (worse symptoms).	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: Pediatric PROMIS® Subscales for adolescents	The Patient-Reported Outcomes Measurement Information System (PROMIS®)-29 Profile is a collection of 4-item short forms assessing anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and the ability to participate in social roles and activities, as well as a single pain intensity item. The Pediatric PROMIS® Subscales will be used for adolescents. The individual scales for fatigue, pain interference, anxiety and depression, each being 5-point Likert scales, and the single pain intensity item, a 0 to 10 Numerical Rating Scale, will be used in this study. A higher score for all these scales indicate poorer HRQL (worse symptoms).	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: HIT-6	The Headache Impact Test (HIT)-6 is a short-form scale, partially derived from the 54-item HIT, and used to measure the impact of headaches in the past 4 weeks on the ability to function at work, at school, at home and in social situations. Items are scored on a 5-point Likert scale ranging from 6=Never, 8=Rarely, 10=Sometimes, 11=Very often, 13=Always, with a global score ranging from 36 to 78, a higher score indicating a worse HRQL.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: Condensed MCMDM-1VWD Bleeding Questionnaire: Bruising Subscale	The Condensed MCMDM-1VWD Bleeding Questionnaire is a bleeding-specific questionnaire used to produce a bleeding score for von Willebrand disease, which was developed by eliminating all details not directly affecting the bleeding score from the validated and extensive MCMDM-1VWD questionnaire. This study will only use the 5 close-ended questions of the bruising scale. These 5 questions assess the presence of bruising (yes/no), location (exposed/unexposed sites) and average size (<1cm, 1 to 5cm and >5cm), presence of minimal or no trauma (yes/no), and whether medical attention was required (yes/no).	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: PDQ-5	The Perceived Deficits Questionnaire 5-Item (PDQ-5) is a subscale of the full-length Perceived Deficits Questionnaire (PDQ), developed specifically for participants with Multiple Sclerosis to assess perceived cognitive deficits from the subject's perspective. The PDQ has 4 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization. The PDQ-5 consists of the 5 PDQ items correlating most strongly with the total PDQ score; items from all 4 subscales are represented.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: NEI-VFQ-25	The National Eye Institute Visual Function Questionnaire (NEI-VFQ or VFQ)-25 is a valid and reliable 25-item version of the 51-item NEI-VFQ. The questionnaire measures the impact of visual impairment on Health Related Quality of Life (HRQL). The general vision (1 item), near vision (3 items), and distant vision activities (3 items) subscales will be used in this study. Each item is associated with a 6-point Likert scale ranging from 1 (no difficulty at all) to 6 (stopped doing this for other reason or not interested in doing this), and global scores range from 0 to 100, a higher score indicating better HRQL.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: WPAI-GH	The self-administered Work Productivity and Activity Impairment-General Health (WPAI-GH) is a 6-item scale measuring work (5 items) and daily activities (1 item). Scores express the impairment percentage so a lower score represents more productivity.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: WPAI-GH plus Classroom Impairment questions for adolescents	The Work Productivity and Activity Impairment (WPAI) plus Classroom Impairment Questionnaire will be used for adolescents. The WPAI plus Classroom Impairment Questionnaire measures school attendance; productivity levels at school; and ability to perform regular daily activities. The WPAI plus Classroom Impairment Questionnaire is a 9-item scale measuring school/work (8 items) and daily activities (1 item). Scores express the impairment percentage so a lower score represents more productivity. While the instructions from the instrument will not be changed, adolescent participants will be instructed to consider their school work and activities when completing the questionnaire.	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: PGI-S	The Patient Global Impression of Severity (PGI-S) is a 1-item questionnaire designed to assess participant's impression of disease severity that was adapted to congenital thrombotic thrombocytopenic purpura (cTTP). The PGI-S item asks the respondent to best describe how their cTTP symptoms severity is now Scores are on a 4-point scale scored as: "normal" (1), "mild" (2), "moderate" (3), or "severe" (4).	Day 1, and Day 14
Change from baseline of Quality of life (QoL) outcomes: PGI-Change	The Patient Global Impression of Change (PGI-C) is a single 1 item questionnaire that compares the participant's current health state to when treatment was started. Response options range from 1 (Very Much Improved) through 4 (No Change) to 7 (Very Much Worse).	Day 1, and Day 14

Collaborators and Investigators

• Sponsor: Baxalta now part of Shire

Publications and helpful links

Helpful Links

• To obtain more information on the study, click here/on this link.

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 12, 2018
• Primary Completion (ACTUAL): April 8, 2019
• Study Completion (ACTUAL): April 8, 2019

Study Registration Dates

• First Submitted: April 23, 2018
• First Submitted That Met QC Criteria: May 7, 2018
• First Posted (ACTUAL): May 9, 2018

Study Record Updates

• Last Update Posted (ACTUAL): March 17, 2021
• Last Update Submitted That Met QC Criteria: March 15, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Hematologic Diseases; Hemorrhage; Blood Coagulation Disorders; Skin Manifestations; Thrombocytopenia; Blood Platelet Disorders; Thrombophilia; Thrombotic Microangiopathies; Purpura; Purpura, Thrombocytopenic; Purpura, Thrombotic Thrombocytopenic
• Other Study ID Numbers: 281701

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
• IPD Sharing Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No